Company / Accounts Receivable
Verrica Pharmaceuticals Inc. Accounts Receivable History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$5.3M
FY2025
5-year range
$48.0K / $5.3M
FY2023-FY2025
Trend
+10858.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable changed +10858% YoY in FY2025, a notable deviation from the 2-year average annual change of +5380%.
Based on SEC 10-K filings.
$5M in FY2025.
Improved from $4M to $5M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, accounts receivable increased 10858.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score -3.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.3M | +10858.3% |
| FY2024 | $48.0K | -98.9% |
| FY2023 | $4.2M | - |
| FY2022 | - | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026